These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

756 related items for PubMed ID: 25258101

  • 21. Febrile seizures after 2010-2011 influenza vaccine in young children, United States: a vaccine safety signal from the vaccine adverse event reporting system.
    Leroy Z, Broder K, Menschik D, Shimabukuro T, Martin D.
    Vaccine; 2012 Mar 02; 30(11):2020-3. PubMed ID: 22361303
    [Abstract] [Full Text] [Related]

  • 22. Postmarketing safety surveillance of trivalent recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System.
    Woo EJ, Moro PL, Cano M, Jankosky C.
    Vaccine; 2017 Oct 09; 35(42):5618-5621. PubMed ID: 28886946
    [Abstract] [Full Text] [Related]

  • 23. Post-Marketing Surveillance of Human Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 1990‒2015.
    Moro PL, Woo EJ, Paul W, Lewis P, Petersen BW, Cano M.
    PLoS Negl Trop Dis; 2016 Jul 09; 10(7):e0004846. PubMed ID: 27410239
    [Abstract] [Full Text] [Related]

  • 24. Guillain-Barré syndrome after vaccination in United States: data from the Centers for Disease Control and Prevention/Food and Drug Administration Vaccine Adverse Event Reporting System (1990-2005).
    Souayah N, Nasar A, Suri MF, Qureshi AI.
    J Clin Neuromuscul Dis; 2009 Sep 09; 11(1):1-6. PubMed ID: 19730016
    [Abstract] [Full Text] [Related]

  • 25. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010.
    Vellozzi C, Broder KR, Haber P, Guh A, Nguyen M, Cano M, Lewis P, McNeil MM, Bryant M, Singleton J, Martin D, DeStefano F.
    Vaccine; 2010 Oct 21; 28(45):7248-55. PubMed ID: 20850534
    [Abstract] [Full Text] [Related]

  • 26. Guillain-Barré syndrome following influenza vaccination.
    Haber P, DeStefano F, Angulo FJ, Iskander J, Shadomy SV, Weintraub E, Chen RT.
    JAMA; 2004 Nov 24; 292(20):2478-81. PubMed ID: 15562126
    [Abstract] [Full Text] [Related]

  • 27. Data mining for prospective early detection of safety signals in the Vaccine Adverse Event Reporting System (VAERS): a case study of febrile seizures after a 2010-2011 seasonal influenza virus vaccine.
    Martin D, Menschik D, Bryant-Genevier M, Ball R.
    Drug Saf; 2013 Jul 24; 36(7):547-56. PubMed ID: 23657824
    [Abstract] [Full Text] [Related]

  • 28. Adverse events following adenovirus type 4 and type 7 vaccine, live, oral in the Vaccine Adverse Event Reporting System (VAERS), United States, October 2011-July 2018.
    McNeil MM, Paradowska-Stankiewicz I, Miller ER, Marquez PL, Seshadri S, Collins LC, Cano MV.
    Vaccine; 2019 Oct 16; 37(44):6760-6767. PubMed ID: 31548014
    [Abstract] [Full Text] [Related]

  • 29. Adverse events after tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine administered to adults 65 years of age and older reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2010.
    Moro PL, Yue X, Lewis P, Haber P, Broder K.
    Vaccine; 2011 Nov 21; 29(50):9404-8. PubMed ID: 21920404
    [Abstract] [Full Text] [Related]

  • 30. Preparation for global introduction of inactivated poliovirus vaccine: safety evidence from the US Vaccine Adverse Event Reporting System, 2000-12.
    Iqbal S, Shi J, Seib K, Lewis P, Moro PL, Woo EJ, Shimabukuro T, Orenstein WA.
    Lancet Infect Dis; 2015 Oct 21; 15(10):1175-1182. PubMed ID: 26289956
    [Abstract] [Full Text] [Related]

  • 31. Signals and trends of Guillain-Barré syndrome after the introduction of live-attenuated vaccines for influenza in the US and South Korean adverse event reporting systems.
    Lee H, Kim HJ, Choe YJ, Shin JY.
    Vaccine; 2020 Jul 22; 38(34):5464-5473. PubMed ID: 32600907
    [Abstract] [Full Text] [Related]

  • 32. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring.
    Vellozzi C, Burwen DR, Dobardzic A, Ball R, Walton K, Haber P.
    Vaccine; 2009 Mar 26; 27(15):2114-20. PubMed ID: 19356614
    [Abstract] [Full Text] [Related]

  • 33. Adverse events following quadrivalent meningococcal diphtheria toxoid conjugate vaccine (Menactra®) reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2016.
    Myers TR, McNeil MM, Ng CS, Li R, Marquez PL, Moro PL, Omer SB, Cano MV.
    Vaccine; 2020 Sep 11; 38(40):6291-6298. PubMed ID: 32747215
    [Abstract] [Full Text] [Related]

  • 34. Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS.
    Halsey NA, Griffioen M, Dreskin SC, Dekker CL, Wood R, Sharma D, Jones JF, LaRussa PS, Garner J, Berger M, Proveaux T, Vellozzi C, Hypersensitivity Working Group of the Clinical Immunization Safety Assessment Network, Broder K, Setse R, Pahud B, Hrncir D, Choi H, Sparks R, Williams SE, Engler RJ, Gidudu J, Baxter R, Klein N, Edwards K, Cano M, Kelso JM.
    Vaccine; 2013 Dec 09; 31(51):6107-12. PubMed ID: 24120547
    [Abstract] [Full Text] [Related]

  • 35. U.S. Postlicensure safety surveillance for adolescent and adult tetanus, diphtheria and acellular pertussis vaccines: 2005-2007.
    Chang S, O'Connor PM, Slade BA, Woo EJ.
    Vaccine; 2013 Feb 27; 31(10):1447-52. PubMed ID: 23142308
    [Abstract] [Full Text] [Related]

  • 36. Adverse events following quadrivalent meningococcal CRM-conjugate vaccine (Menveo®) reported to the Vaccine Adverse Event Reporting system (VAERS), 2010-2015.
    Myers TR, McNeil MM, Ng CS, Li R, Lewis PW, Cano MV.
    Vaccine; 2017 Mar 27; 35(14):1758-1763. PubMed ID: 28262331
    [Abstract] [Full Text] [Related]

  • 37. Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021-June 30, 2022.
    Moro PL, Zhang B, Ennulat C, Harris M, McVey R, Woody G, Marquez P, McNeil MM, Su JR.
    Vaccine; 2023 Mar 10; 41(11):1859-1863. PubMed ID: 36669964
    [Abstract] [Full Text] [Related]

  • 38. Reports of cell-based influenza vaccine administered during pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 2013-2020.
    Moro PL, Marquez P.
    Vaccine; 2021 Jan 22; 39(4):678-681. PubMed ID: 33358703
    [Abstract] [Full Text] [Related]

  • 39. The reporting sensitivity of the Vaccine Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barré syndrome.
    Miller ER, McNeil MM, Moro PL, Duffy J, Su JR.
    Vaccine; 2020 Nov 03; 38(47):7458-7463. PubMed ID: 33039207
    [Abstract] [Full Text] [Related]

  • 40. Postmarketing safety surveillance for typhoid fever vaccines from the Vaccine Adverse Event Reporting System, July 1990 through June 2002.
    Begier EM, Burwen DR, Haber P, Ball R, Vaccine Adverse Event Reporting System Working Group.
    Clin Infect Dis; 2004 Mar 15; 38(6):771-9. PubMed ID: 14999618
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 38.